Skip to main content
Deutsch

Search

  1. Home
  2. Search

Webseiten-Inhalte

Anaplastic Large Cell Lymphoma: combination therapy recommended to prevent treatment resistance ... of researchers led by molecular biologist Suzanne Turner from the University of Cambridge/Masaryk University Brno (CZ) and involving molecular pathologist Lukas Kenner from the MedUni Vienna, has now discovered a specific defence mechanism against certain drugs (ALK inhibitors), which promotes cancer... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-juli-2020/anaplastic-large-cell-lymphoma-combination-therapy-recommended-to-prevent-treatment-resistance/medicine-science/
Detailsite | MedUni Vienna ...All News A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/cancer-driver-gene-reduces-metastasis-in-prostate-cancer/
Detailsite | MedUni Vienna ... founded by Lukas Kenner (MedUni Vienna), the Salzburg scientist Olaf Merkel as well as Suzanne Turner (Cambridge / Great Britain). Only last year Kenner and Merkel discovered possible causes for lymph node cancer. They published their findings last year in the US science journal “PNAS”.“For lymphomas there is typically the pathological matching of chromosomes, which combines genes, which are otherwise not joined together, into a hybrid protein molecule”, according to Kenner. These molecules lead to severe activation in the tumours of the regulatory gene ALK, which normally transmits growth signals... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/scientists-discussed-new-treatment-approaches-in-lymph-node-cancer/
Research into use of diabetes medication for treatment of metastatic prostate cancer ... the prestigious journal Molecular Cancer. Using a complex mouse model, the research team under Lukas Kenner (MedUni Vienna Department of Pathology, Department of Laboratory Animal Pathology at Vetmeduni Vienna) examined prostate cancer cells and identified the key factors in the regulation of tumour... https://www.meduniwien.ac.at/web/en/about-us/news/2023/news-in-august-2023/research-into-use-of-diabetes-medication-for-treatment-of-metastatic-prostate-cancer/medicine-science/
Research into use of diabetes medication for treatment of metastatic prostate cancer ... the prestigious journal Molecular Cancer. Using a complex mouse model, the research team under Lukas Kenner (MedUni Vienna Department of Pathology, Department of Laboratory Animal Pathology at Vetmeduni Vienna) examined prostate cancer cells and identified the key factors in the regulation of tumour... https://www.meduniwien.ac.at/web/en/about-us/news/2023/news-in-august-2023/research-into-use-of-diabetes-medication-for-treatment-of-metastatic-prostate-cancer/
Prostate cancer: New AI model can prevent unnecessary prostate removals ... recently published in the journal "Theranostics". The research team led by Lukas Kenner (MedUni Vienna's Department of Pathology), Jing Ning and Clemens Spielvogel (MedUni Vienna's Department of Biomedical Imaging and Image-Guided Therapy) aimed to develop a new machine learning model for more precise tumor assessment. "We combined multi-omics technology with artificial intelligence applications," says Lukas Kenner, head of the study, emphasizing the unique approach. Multiomics is a method in medical research in which various "omics" data sources such as genetic information (genomics), imaging... https://www.meduniwien.ac.at/web/en/about-us/news/2024/news-in-september-2024/prostate-cancer-new-ai-model-can-prevent-unnecessary-prostate-removals/medicine-science/
Prostatakrebs: Neues KI-Modell kann unnötige Prostata-Entfernungen verhindern ... beste Option darstellt. Unnötige Eingriffe bei Patienten mit geringerem Risiko für eine Ausbreitung des Tumors können so vermieden werden. Die Studie wurde kürzlich im Fachjournal „Theranostics“ publiziert. Das Forschungsteam um Lukas Kenner (Klinisches Institut für Pathologie der MedUni Wien), Jing... https://www.meduniwien.ac.at/web/ueber-uns/news/2024/news-im-september-2024/prostatakrebs-neues-ki-modell-kann-unnoetige-prostata-entfernungen-verhindern/medizin-wissenschaft/
Prostatakrebs: Neues KI-Modell kann unnötige Prostata-Entfernungen verhindern ... beste Option darstellt. Unnötige Eingriffe bei Patienten mit geringerem Risiko für eine Ausbreitung des Tumors können so vermieden werden. Die Studie wurde kürzlich im Fachjournal „Theranostics“ publiziert. Das Forschungsteam um Lukas Kenner (Klinisches Institut für Pathologie der MedUni Wien), Jing... https://www.meduniwien.ac.at/web/ueber-uns/news/2024/news-im-september-2024/prostatakrebs-neues-ki-modell-kann-unnoetige-prostata-entfernungen-verhindern/
Prostate cancer: New AI model can prevent unnecessary prostate removals ... recently published in the journal "Theranostics". The research team led by Lukas Kenner (MedUni Vienna's Department of Pathology), Jing Ning and Clemens Spielvogel (MedUni Vienna's Department of Biomedical Imaging and Image-Guided Therapy) aimed to develop a new machine learning model for more precise tumor assessment. "We combined multi-omics technology with artificial intelligence applications," says Lukas Kenner, head of the study, emphasizing the unique approach. Multiomics is a method in medical research in which various "omics" data sources such as genetic information (genomics), imaging... https://www.meduniwien.ac.at/web/en/about-us/news/2024/news-in-september-2024/prostate-cancer-new-ai-model-can-prevent-unnecessary-prostate-removals/
Posterpreise an Nachwuchsforscher des Klinischen Instituts für Pathologie der MedUni Wien ... anaplastic large cell lymphoma“ Jan Pencik aus der Gruppe von Lukas Kenner wurde prämiert mit seiner Arbeit: „Aberrant STAT3-AMPK signaling targets distinct subgroups of lethal prostate cancer“ Jan Pencik studierte in Olomouc und Brno (Tschechische Republik) Biochemie in den Jahren von 2005 bis 2009. Er absolvierte einen Forschungsaufenthalt an der Universität Stuttgart (Deutschland), bevor er 2010 am LBI-CR in Wien bei Lukas Kenner seine Doktorarbeit begann. Seither widmete er sich am Ludwig Boltzmann-Institut und am Klinischen Institut für Pathologie der MedUni Wien der Analyse eines Mausmodells zur Entstehung von Prostasta-Krebs durch die Inaktivierung von IL-6/STAT3 oder/und PTEN, was zur Veröffentlichung dieser Studie führte. Die Studie entstand unter Leitung von Lukas Kenner und Brigitte Hantusch innerhalb eines Kooperationsprojekts mit der klinischen Abteilung für Nuklearmedizin und dem Center for... https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2017/news-im-september-2017/posterpreise-an-nachwuchsforscher-des-klinischen-instituts-fuer-pathologie-der-meduni-wien/